In the last few years, we have seen an uptick in behavioral health groups focused on psychedelic treatments. Ketamine remains a controlled substance and ketamine behavioral health remains an industry with material regulatory risks.
Creso Announced That its Total Q1 2021 Revenue Was A$1,385,000 – up 237% From Q4 2020
Creso Pharma (ASX: CPH) (OTC:COPHF) (FRA: 1X8) announced the release of its Quarterly Activities Report for the period ended 31 March 2021, together with its Appendix 4C Quarterly Cash Flow Report. “This quarter marked Creso’s evolution into a broader-based pharmaceutical company. Having undertaken a thorough search for quality, complementary acquisition opportunities, the company successfully identified and secured an agreement with psychedelics company, Halucenex, which, if approved by shareholders, will represent a significant milestone for the company, as it looks to commercialize new psychedelic-assisted psychotherapy treatments. Halucenex has made considerable progress during the quarter and provides Creso with access to another lucrative vertical,” said Adam Blumenthal, Creso Pharma Non-Executive Chairman.